Industry news

The epilepsy therapeutics market in the APAC to grow at a CAGR of 5.78 percent over the period 2014-2019 according to new research report

WhaTech

The Epilepsy Therapeutics market in the APAC to grow at a CAGR of 5.78 percent over the period 2014-2019.

Gentleman aims to use 23andMe's R&D blank slate to tip in vivo-in silico testing balance

Nick Paul Taylor / Fierce Biotech IT

Robert Gentleman has shared details of what he wants to achieve as 23andMe's VP of computational biology. And the ex-Genentech bioinformatics chief is looking to turn 23andMe's inexperience in drug discovery into a strength, notably by relying more on computational methods to generate data in early-stage tests.

Pakistan seen as hot pharma growth market

EJ Lane / FeircePharmaAsia

Some of the Asia-Pacific region's major countries can expect continued increases in pharmaceutical expenditures during the third quarter, led, surprisingly, by Pakistan.

Quintiles homes in on Asian biotech with its latest offering

Damian Garde / FierceCRO

Quintiles, the world's largest CRO, is targeting the growing number of small and midsize biotech companies in Asia, porting its bespoke offering to the region in hopes of partnering with the continent's up-and-coming drug developers.

29 May 2015

Genetic Analysis of Single Circulating Tumor Cells Shows High Intra-patient Heterogeneity

Epic Sciences announced today that the company will present single cell sequencing data, from metastatic castrate resistant prostate cancer patients, at the 2015 annual meeting of the American Society for Clinical Oncology. This application expands the investigational utility of Epic Sciences' no cell left behind™ platform to characterize circulating tumor cell (CTC) genomic alterations. The study revealed that late stage patients have heterogeneous clonal CTC populations harboring separate genetic alterations. 

IPR challenge could up the ante of defending drug patents

Mari Serebrov / BioWorld

Defending patents for drugs and medical devices is part of the stakes of an R&D budget, but the size of that stake could increase significantly if a hedge fund manager wins his inter partes review (IPR) challenge of selected drug patents.

CROs/CMOs Powering Vaccine R&D At Biotechs

Louis Garguilo / Outsourced Pharma

The first is about vaccine shortages and cutting R&D investment. Chacón’s is a positive tale of a growing number of startups and biotechs utilizing CROs/CMOs to create a new R&D industry for innovative vaccines. The antagonists in the first case – placing price ahead of access and free-markets – are the very organizations Chacón lionizes above.

New Push Ties Cost of Drugs to How Well They Work

Peter Loftus / The Wall Street Journal

Express Scripts Holding Co., a large manager of prescription-drug benefits for U.S. employers and insurers, is seeking deals with pharmaceutical companies that would set pricing for some cancer drugs based on how well they work.

Russia gives green light to parallel imports in bid to lower prices

Alexei Lossan / Russia Beyond the Headlines

The Russian government has given its approval to parallel imports, meaning that it will be possible to import some goods for sale in Russia without rights holder permission. The government hopes that this decision will lead to a drop in prices, but experts say that its major consequence will be an increase in counterfeit goods. Moreover, the measure is contrary to the norms of the Eurasian Economic Union, the key integration union on the territory of the former USSR.

Russia makes it easier to skirt imported drug sale norms

EJ Lane / FeircePharmaAsia

Moscow is opening a gray market to allow imports of drugs intended for sale in other countries to be sold in Russia without the consent of the maker with a trademark for the product. The government hopes the move will lower pharmaceutical costs.